We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Jennie  Lill - Executive Director, Microchemistry, Proteomics, Lipidomics and NGS

Jennie Lill

Executive Director, Microchemistry, Proteomics, Lipidomics and NGS

Postdoc Mentor
"My inspiration comes from the enthusiasm and dedication of my team and collaborators. I am extremely proud to be part of this rewarding endeavor and excited to see our current early stage drug discovery research & technology development projects come to fruition."
Years at Genentech
Publications at Genentech
Awards & Honors

I decided to pursue a career at Genentech as it presented the opportunity to join a world-leading research environment.

As the leader of the Proteomics & NGS department, I am involved in many projects encompassing a variety of disciplines and cutting-edge drug discovery research topics. In addition to these collaborations, I also have the opportunity to initiate novel biochemical and mass spectrometric technology development projects.

Postdoctoral Mentor

I enjoy seeing the creativity of our new generation of scientists and enjoy playing a key role in nourishing their enthusiasm for science.

Featured Publication

Loss of the tumor suppressor BAP1 causes myeloid transformation.

Science. 2012 Sep 21;337(6101):1541-6. Epub 2012 Aug 9.

Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC,Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM.